Background
The concept of blastomatoid carcinosarcoma (BCS) was initially proposed by Yukio et al. in their study of classic pulmonary blastoma (CPB) and related neoplasms [
1]. By definition, these tumors were categorized into one variant of carcinosarcoma with variable high-grade fetal lung adenocarcinoma (H-FLAC)/clear cell adenocarcinoma and primitive mesenchymal components. Unlike CPB, both components in BCS harbored no missense mutations of the β-catenin gene. The current WHO classification suggested these entities should be classified as carcinosarcoma and the characteristic components be mentioned in pathological report [
2]. However, the exact clinicopathologic features and genomic abnormalities of BCS are still poorly understood.
In clinical practice, the diagnosis and classification of pulmonary biphasic differentiated tumors is very difficult. These entities include conventional carcinosarcoma, pulmonary blastoma, pleomorphic carcinomas and few cases of synovial sarcoma. Pulmonary blastoma (PB) can be diagnosed based on typical low-grade fetal lung adenocarcinoma (L-FLAC) and unique genetic alteration involving Wnt signaling pathway which results aberrant nuclear expression of β-catenin in both epithelial and mesenchymal cells [
3,
4]. Pulmonary carcinosarcoma is defined by a mixture of non-small cell lung carcinoma and heterologous sarcomas components and can be recognized by lacking the L-FLAC and primitive mesenchymal components [
5,
6]. In addition, some gene mutations, such as TP53 mutation, commonly presented in carcinosarcoma, may assist in diagnosis [
7,
8]. Nevertheless, BCS seems to represent a special subtype of biphasic differentiated lung cancer, not only because of its unique morphology and immunophenotype, but also the complex molecular alterations and biological behavior. At the same time, some cases may be missed or misdiagnosed due to the disunity of diagnostic criteria.
In this study, we investigated the clinicopathologic characteristics of three cases of BCS and profiled the genetic abnormalities against epithelial and mesenchymal components. We emphasized the significance of morphologic identification and the role of immunohistochemistry and genomic analysis in auxiliary diagnosis. Besides, the treatment strategies and corresponding curative effects complemented each other, could also providing a more comprehensive understanding of BCS.
Discussion
Since Yukio et al. proposed the concept of blastomatoid carcinosarcoma (BCS) and described 5 cases of such lesions in 2004 [
1], some primary biphasic differentiation lung tumors with blastomatoid mesenchymal under this terminology had been reported in succession [
16‐
18]. Nevertheless, BCS may share similarities with pulmonary blastoma (PB) and carcinosarcoma in morphology and genetic abnormalities. This definition may cause problems in pathological diagnosis and clinical treatment.
The epithelial components of PB are essentially low-grade fetal lung adenocarcinoma (L-FLAC) and very few cases mixed with or contained pure high-grade fetal lung adenocarcinoma (H-FLAC) component [
19,
20]. H-FLAC components may also present in few cases of carcinosarcoma, thus interfering with pathological diagnosis [
21,
22]. Including the first defined cases, the epithelial components in reported BCS are mainly H-FLAC and/or clear cell adenocarcinoma. Other non-small cell lung cancer components, such as enteric adenocarcinoma, spindle cell and giant cell carcinoma and mucinous adenocarcinoma, have not been reported. The mesenchymal components mostly showed no tendency to maturate except for the cases reported by Sakane T et al. in which the stromal cells differentiated into chondrosarcoma [
18]. And in our study, enteric adenocarcinoma was seen in one case and differentiated sarcoma components were not found.
Immunohistochemistry may be of limited use on the establishment of diagnosis, after all, there is no specific immunological markers for H-FLAC and primitive stromal cells [
23]. And up to now, morphology is still the basis of pathological diagnosis for BCS. But immunohistochemical staining for Ki-67 proliferation index may be useful for distinguishing between BCS and conventional carcinosarcoma. As depicted in our cases, the epithelial and mesenchymal components respectively exhibit consistent bipolar proliferative activity. The proliferation index of epithelial components was much higher than that of mesenchymal.
Previous studies demonstrate that
CTNNB1 mutation and subsequent activation of the Wnt signaling pathway play an important role in tumorigenesis of L-FLAC and PB tumors, but not in carcinosarcoma [
1,
3,
4]. Besides, few cases of PB were found to harbor somatic
DICER1 missense mutation and indicated that
DICER1 may be closely related to these tumors presenting later in life [
24]. Our results demonstrated that aberrant nuclear expression of β-catenin and missense mutation of
CTNNB1 and
DICER1 were found only in L-FLAC component but not in both H-FLAC and mesenchymal components which was further supported by previous studies [
25]. Moreover, our results showed that
FAT1 and
FAT3 gene missense mutations coexisted in the epithelial and mesenchymal cells in patient 1. Both
DICER1 and
FAT mutations had not been reported in previous cases of BCS. The human
FAT1 and
FAT3 gene encode large proteins with extracellular cadherin repeats that are associated with neurodevelopment and cell migration and are most homologous, which involved in tumor suppression [
26]. In addition, some genetic alterations, such as
BRCA2 and
KAT6A only occurred in H-FLAC while
FUBP1, RICTOR, and
CREBBP only existed in mesenchymal components indicating the phenotypic heterogeneity among H-FLAC, L-FLAC and mesenchymal cells.
We agree that the occurrence of BCS, classical PB and carcinosarcoma are due to a group of genetic abnormalities in both epithelial and mesenchymal components [
27]. Conservative or consistent genomic changes in both components play a decisive role in the development, and are also one of the criteria in molecular diagnosis for corresponding entities. At the same time, tumor cells evolve gradually with the accumulation of genetic alterations and present these intrinsic changes in morphology and immunophenotype [
28].
There is still insufficient clinical evidence for standardized treatment and available recommendations for BCS and related tumors. From our clinical experience, early stage BCS tumors less than 4 cm without lymphatic and hematogenous metastasis could benefit from combined surgical resection and chemotherapy. More clinical cases, follow-up information, and comprehensive genetic analysis may be helpful for explaining the behavior of BCS and subsequent treatment strategy.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.